RCT | Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis.
29 Aug, 2022 | 11:58h | UTCUpadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)